INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Ultragenyx PharmaceuticalUltragenyx Pharmaceutical(US:RARE) Businesswire·2026-02-14 11:10

公司事件核心观点 - Ultragenyx公司被指控在关于其药物setrusumab降低骨折率的潜在三期研究成功可能性方面误导了投资者 [1] 公司产品与研发进展 - 涉事药物为setrusumab 正在进行针对降低骨折率的三期研究 [1]

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Reportify